An Emory University team identified a 10-protein plasma signature that distinguished ALS patients from healthy controls with 98.3% balanced accuracy in a separate validation cohort, compared with 89.9% for neurofilament light chain alone. Six of the ten proteins had not previously been reported as ALS blood biomarkers, and one, FOLR1, corrected false alarms caused by elevated NFL in people without the disease. The finding remains preclinical research, validated against healthy controls rather than other neurological conditions.
Key Points
- Ten-protein plasma panel reached 98.3% balanced accuracy versus 89.9% for NFL
- Six proteins never previously linked to ALS in blood
- Validation used only 37 controls; no comparison against mimicking neurological conditions
Longevity Analysis
Single-marker testing fails when one signal is noisy — elevated neurofilament appears in people without ALS, and a lone protein cannot distinguish nerve damage from its many causes. Reading hundreds of neurological and inflammatory proteins simultaneously allows the pattern across markers to carry the information, which is the direction functional assessment of the nervous system is moving: inferring what is happening in tissue that cannot be sampled directly. The practical value for healthy aging depends on whether such panels eventually track gradual decline rather than confirm established disease, and that case has not yet been made.
Original published by Longevity.Technology, by Kyle Umipig.